Lukas Lannemyr

Lukas Lannemyr

Auto-generated profile, based on publicly available information

Lukas Lannemyr

Department of Anaesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Section of Cardiothoracic Anaesthesia and Intensive Care

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Anesthesiology
Verified
Journal Article
Closed access
LLLukas Lannemyr
Lukas Lannemyr
GBGudrun Bragadottir
Gudrun Bragadottir
VKVitus Krumbholz
Vitus Krumbholz
BRBengt Redfors
Bengt Redfors
JSJohan Sellgren
Johan Sellgren
SRSven-Erik Ricksten
Sven-Erik Ricksten
Background: Acute kidney injury is a common complication after cardiac surgery with cardiopulmonary bypass. The authors evaluated the effects of normothermic cardiopulmonary bypass on renal blood flow, glomerular filtration rate, renal oxygen consumption, and renal oxygen supply/demand relationship, i.e., renal oxygenation (primary outcome) in patients undergoing cardiac surgery. Methods: Eighteen patients with a normal preoperative serum creatinine undergoing cardiac surgery procedures with normothermic cardiopulmonary bypass (2.5 l · min−1 · m−2) were included after informed consent. Systemic and renal hemodynamic variables were measured by pulmonary artery and renal vein catheters before, during, and after cardiopulmonary bypass. Arterial and renal vein blood samples were taken for measurements of renal oxygen delivery and consumption. Renal oxygenation was estimated from the renal oxygen extraction. Urinary N-acetyl-β-d-glucosaminidase was measured before, during, and after cardiopulmonary bypass. Results: Cardiopulmonary bypass induced a renal vasoconstriction and redistribution of blood flow away from the kidneys, which in combination with hemodilution decreased renal oxygen delivery by 20%, while glomerular filtration rate and renal oxygen consumption were unchanged. Thus, renal oxygen extraction increased by 39 to 45%, indicating a renal oxygen supply/demand mismatch during cardiopulmonary bypass. After weaning from cardiopulmonary bypass, renal oxygenation was further impaired due to hemodilution and an increase in renal oxygen consumption, accompanied by a seven-fold increase in the urinary N-acetyl-β-d-glucosaminidase/creatinine ratio. Conclusions: Cardiopulmonary bypass impairs renal oxygenation due to renal vasoconstriction and hemodilution during and after cardiopulmonary bypass, accompanied by increased release of a tubular injury marker.

21 August 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
LLLukas Lannemyr
Lukas Lannemyr
SRSven‐Erik Ricksten
Sven‐Erik Ricksten
BRBengt Rundqvist
Bengt Rundqvist
BABert Andersson
Bert Andersson
SBSven‐Erik Bartfay
Sven‐Erik Bartfay
KKKristjan Karason
Kristjan Karason
Background: The management of the cardiorenal syndrome in advanced heart failure is challenging, and the role of inotropic drugs has not been fully defined. Our aim was to compare the renal effects of levosimendan versus dobutamine in patients with heart failure and renal impairment. Methods and Results: In a randomized double‐blind study, we assigned patients with chronic heart failure (left ventricular ejection fraction <40%) and impaired renal function (glomerular filtration rate <80 mL/min per 1.73 m 2 ) to receive either levosimendan (loading dose 12 μg/kg+0.1 μg/kg per minute) or dobutamine (7.5 μg/kg per minute) for 75 minutes. A pulmonary artery catheter was used for measurements of systemic hemodynamics, and a renal vein catheter was used to measure renal plasma flow by the infusion clearance technique for PAH (para‐aminohippurate) corrected by renal extraction of PAH . Filtration fraction was measured by renal extraction of chromium ethylenediamine tetraacetic acid. A total of 32 patients completed the study. Following treatment, the levosimendan and dobutamine groups displayed similar increases in renal blood flow (22% and 26%, respectively) with no significant differences between groups. Glomerular filtration rate increased by 22% in the levosimendan group but remained unchanged in the dobutamine group ( P =0.012). Filtration fraction was not affected by levosimendan but decreased by 17% with dobutamine ( P =0.045). Conclusions: In patients with chronic heart failure and renal impairment, levosimendan increases glomerular filtration rate to a greater extent than dobutamine and thus may be the preferred inotropic agent for treating patients with the cardiorenal syndrome. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT 02133105.

1 February 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
LLLukas Lannemyr
Lukas Lannemyr
GBGudrun Bragadottir
Gudrun Bragadottir
AHAnders Hjärpe
Anders Hjärpe
BRBengt Redfors
Bengt Redfors
SRSven-Erik Ricksten
Sven-Erik Ricksten

12 June 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
MTMaria Tholén
Maria Tholén
SRSven-Erik Ricksten
Sven-Erik Ricksten
LLLukas Lannemyr
Lukas Lannemyr
Background: Acute kidney injury (AKI) is a common and serious complication after cardiac surgery, and current strategies aimed at treating AKI have proven ineffective. Levosimendan, an inodilatating agent, has been shown to increase renal blood flow and glomerular filtration rate in uncomplicated postoperative patients and in patients with the cardiorenal syndrome. We hypothesized that levosimendan through its specific effects on renal vasculature, a preferential vasodilating effect on preglomerular resistance vessels, could improve renal function in AKI-patients with who did not have clinical indication for inotropic support. Methods: In this single-center, double-blind, randomized controlled study, adult patients with postoperative AKI within 2 days after cardiac surgery, who were hemodynamically stable with a central venous oxygen saturation (ScvO2) ≥ 60% without inotropic support were eligible for inclusion. After randomization, study drug infusions, levosimendan (n = 16) or placebo (n = 13) were given for 5 h. A bolus infusion of levosimendan (12 µg/kg), were given for 30 min followed by 0.1 µg/kg/min for 5 h. Renal blood flow and glomerular filtration rate were measured using infusion clearance of para-aminohippuric acid and a filtration marker, respectively. As a safety issue, norepinephrine was administered to maintain mean arterial pressure between 70–80 mmHg. Intra-group differences were tested by Mann–Whitney U-tests, and a linear mixed model was used to test time and group interaction. Results: Twenty-nine patients completed the study. At inclusion, the mean serum creatinine was higher in the patients randomized to levosimendan (148 ± 29 vs 127 ± 22 µmol/L, p = 0.030), and the estimated GFR was lower (46 ± 12 vs 57 ± 11 ml/min/1.73 m2, p = 0.025). Levosimendan induced a significantly (p = 0.011) more pronounced increase in renal blood flow (15%) compared placebo (3%) and a more pronounced decrease in renal vascular resistance (− 18% vs. − 4%, respectively, p = 0.043). There was a trend for a minor increase in glomerular filtration rate with levosimendan (4.5%, p = 0.079), which did differ significantly from the placebo group (p = 0.440). The mean norepinephrine dose was increased by 82% in the levosimedan group and decreased by 29% in the placebo group (p = 0.012). Conclusions: In hemodynamically stable patients with AKI after cardiac surgery, levosimendan increases renal blood flow through renal vasodilatation. Trial registration NCT02531724, prospectly registered on 08/20/2015. https://clinicaltrials.gov/ct2/show/NCT02531724?cond=AKI&cntry=SE&age=1&draw=2&rank=1

26 July 2017 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
LLL. Lannemyr
L. Lannemyr
ELE. Lundin
E. Lundin
BRB. Reinsfelt
B. Reinsfelt
GBG. Bragadottir
G. Bragadottir
BRB. Redfors
B. Redfors
SRS.‐E. Ricksten
S.‐E. Ricksten

1 June 2020 in Journal of Critical Care
Verified
Journal Article
Closed access
LLLukas Lannemyr
Lukas Lannemyr
GBGudrun Bragadottir
Gudrun Bragadottir
BRBengt Redfors
Bengt Redfors
SRSven-Erik Ricksten
Sven-Erik Ricksten